Genprex, Inc. (GNPX)

2.0400 +0.0200 (+0.99%) At close: 04:00PM EDT

Genprex, Inc.

3300 Bee Cave Road
Suite 650-227
Austin, TX 78746
United States
877-774-4679
https://www.genprex.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 26

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Mark S. Berger M.D.	Chief Medical Officer	528.16k	N/A	1955
Mr. Ryan M. Confer M.S.	President, CEO, CFO & Director	606.57k	N/A	1982
Mr. David M. Schloss	Senior Vice President of Human Resources	N/A	N/A	N/A
Mr. Thomas C. Gallagher Esq.	Senior Vice President of Intellectual Property & Licensing	N/A	N/A	N/A
Dr. Suzanne Thornton-Jones	Senior Vice President of Regulatory Affairs & Quality	N/A	N/A	N/A
Dr. Jack A. Roth F.A.C.S., M.D.	Chairman of Scientific & Medical Advisory Board	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC. Its three lung cancer clinical programs have received a Fast Track Designation from the FDA for the treatment of that patient population, and SCLC program has received an FDA Orphan Drug Designation. The company's diabetes gene therapy comprises of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, its GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which produce insulin but distinct enough from beta cells to evade the body's immune system; and GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

Corporate governance

Genprex, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.